PeptideCompareTesofensine — EU research guide.
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, noradrenaline) originally developed for Parkinson's and Alzheimer's disease, repurposed for obesity research due to its strong appetite-suppressing effects.
What is Tesofensine?
Tesofensine is not a peptide but a small-molecule reuptake inhibitor. It simultaneously blocks transporters for serotonin (SERT), dopamine (DAT) and noradrenaline (NET), increasing CNS levels of all three monoamines. This produces strong appetite suppression and mild sympathomimetic effects. It was studied for neurodegeneration before its weight-loss potential was recognised.
What does the research show?
Phase 2 obesity trials showed dose-dependent weight loss of 4.5%, 9.2% and 10.6% at 0.25/0.5/1.0mg over 24 weeks — among the higher figures seen for any single agent in comparable timeframes, though the pivotal trial carries an unresolved 2013 Lancet Expression of Concern over adverse-event reporting. Side effects including elevated heart rate and blood pressure led to cautious dosing. No Phase 3 completion or approval as of mid-2026.
EU legal status
Not approved anywhere. Available as a research chemical. Note: tesofensine is a CNS-active compound and its regulatory classification varies by country. Check local regulations before ordering.
Molecular information
Pharmacokinetics
Tesofensine across EU suppliers
COA-verified EU vendors · Updated monthly
Frequently asked questions
What is tesofensine? ▾
Tesofensine (development code NS-2330) is a small-molecule triple monoamine reuptake inhibitor. It blocks the serotonin, dopamine and noradrenaline transporters at once, raising CNS levels of all three, which suppresses appetite. It is not a peptide.
Is tesofensine a peptide? ▾
No. It is a small-molecule phenyltropane derivative (C17H23Cl2NO, 328.28 g/mol), which sets it apart from the peptides that make up most of this encyclopedia.
What does the obesity research show? ▾
Phase 2 trials reported dose-dependent weight loss of 4.5%, 9.2% and 10.6% at 0.25/0.5/1.0 mg over 24 weeks, though the pivotal trial carries an unresolved 2013 Lancet Expression of Concern over adverse-event reporting. No Phase 3 has been completed and it is not approved as of mid-2026.
Is tesofensine approved or legal in the EU? ▾
It is not approved by the EMA or any regulator and is sold as a research chemical. Because it is CNS-active, its legal classification differs between EU member states, so check local rules before ordering.
Why does tesofensine raise heart rate and blood pressure? ▾
Increased noradrenaline signalling gives it mild sympathomimetic activity, which can raise heart rate and blood pressure. This cardiovascular effect is why trials used cautious dosing.
Is tesofensine banned in sport? ▾
It is not currently on the WADA prohibited list, but CNS stimulant-type compounds are subject to review, so athletes should confirm the current list before use.
References
- Pivotal phase II RCT showing dose-dependent weight loss with tesofensine over 24 weeks in 203 adults with obesity. Astrup A, et al. Lancet. 2008;372(9653):1906–1913. DOI PubMed 18950853
- Formal expression of concern issued after a Danish regulatory audit found investigators had been wrongly instructed not to register certain pre-existing conditions (headache, migraine, stress, depression) as adverse events at two of the five trial sites — unresolved as of 2026. The Lancet Editors. Lancet. 2013;381(9873):1167. DOI PubMed 23561987